戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1                                              PI-3K activates Akt by phosphorylation of threonine 308
2                                              PI-3K activity in capsule-epithelium and fiber cell laye
3                                              PI-3K activity was found in both lens epithelial cells a
4                                              PI-3K inhibitors wortmannin and LY294002 blocked the IGF
5                                              PI-3K initiates a cell signaling pathway that inhibits a
6                                              PI-3K signaling is known to regulate protein translation
7                                              PI-3K, in turn, regulated 2 distinct pathways.
8 uction, while the recruitment of PI-3Kinase (PI-3K) is necessary but not sufficient for this effect.
9                                            A PI-3K inhibitor blocked Akt phosphorylation in JSRV Env-
10 ding FLIP, and protect from Apo2L/TRAIL in a PI-3K/Akt-dependent manner.
11          Furthermore, we found that Akt is a PI-3K downstream mediator for 5-MCDE-induced AP-1 transa
12 Akt induce NF-kappaB activation, Ly294002 (a PI-3K inhibitor), dominant-negative PI-3K, and kinase-de
13                        Thus, activation of a PI-3K/Akt signaling pathway is required for cytokine-dep
14 inase reduces cell-matrix adhesion through a PI-3K-dependent, but ROCK-independent, mechanism.
15 the AP-1 induction is specifically through a PI-3K/Akt-dependent and p70(S6K)-independent pathway.
16 ation and Cap43 protein expression through a PI-3K/Akt-dependent and p70(S6k)-independent pathway.
17 ion, protects cells from apoptosis through a PI-3K/Akt/Bad pathway but not through an ERK1/2 pathway.
18 ocytes from mice deficient in the class I(A) PI-3K p85alpha regulatory subunit.
19 t hyperactivation of the p21(ras)-class I(A) PI-3K pathway is the mechanism for this phenotype.
20 intercrosses between Nf1 +/- and class I (A)-PI-3K-deficient mice, we demonstrate that hyperactivatio
21                                 Accordingly, PI-3K is involved in TPO-mediated inhibition of apoptosi
22 leaving the mechanism by which they activate PI-3K unclear.
23 /ERK activation but only minimally activated PI-3K and Akt.
24 n inactivation (and by extension, activation PI-3K signaling) on myelinating oligodendrocytes and the
25                Whereas constitutively active PI-3K and Akt induce NF-kappaB activation, Ly294002 (a P
26 hibited CEC transmigration without affecting PI-3K activity.
27 s were stimulated with insulin or IGF-1, and PI-3K activity was determined after immunoprecipitation
28 egulated serine/threonine kinase (ERK-2) and PI-3K by expression of dominant-negative proteins or che
29  increased survival signaling via GM-CSF and PI-3K and reduced ROS and apoptosis.
30 ments to determine the control of GM-CSF and PI-3K by calmodulin in Amo showed that GM-CSF expression
31             IGF-1 activated the MAPK/ERK and PI-3K pathways.
32 A, Casein kinase-II, and the Raf-MEK-ERK and PI-3K-Akt pathways, are not required for HSF1-mediated n
33  to TrkB, and heightened downstream ERK2 and PI-3K activities in prefrontal cortex and in lymphocytes
34 lin in Amo showed that GM-CSF expression and PI-3K activation could not be induced when calmodulin wa
35  reported an interaction between the HIF and PI-3K/Akt pathways in HER2-overexpressing cancer cells.
36 rly pathway dependent on tyrosine kinase and PI-3K and a late pathway dependent on protein kinase C.
37             The contribution of the MAPK and PI-3K pathways and, where possible, individual elements
38 rough manipulation of the PI-3K/Akt/mTOR and PI-3K/GSK-3beta/APC pathways.
39 by inhibiting their association with p38 and PI-3K.
40 lar leakage; NF-kappaB, HIF-1alpha, p38, and PI-3K activity; and VEGF, TNF-alpha, and IL-1beta levels
41                    MEK inhibitor PD98059 and PI-3K inhibitors wortmannin and LY294002 inhibited a car
42 f the compounds were potent mixed DNA-PK and PI-3K inhibitors.
43 ndent with maximal benefit seen when PKB and PI-3K were inhibited before ischaemia or during both isc
44 igration by activation of PI-3K/PKCmicro and PI-3K/RhoA pathways independent of Akt.
45 plicated in control of GM-CSF production and PI-3K activation in other immune cell types.
46 via this receptor, whereas NF-kappaB/Rel and PI-3K are crucial for CD40-induced proliferation.
47          This process is mediated by SOS and PI-3K and requires coordinate upstream signals through S
48 tion, suggesting the contribution of another PI-3K family members in MEK1/2 and p42/44ERK activation.
49 nduced AP-1 transactivation, whereas another PI-3K downstream kinase, p70(S6K), was not involved in A
50 e of the mechanisms by which ZNF217 augments PI-3K/Akt signaling.
51  interest because it provided a link between PI-3K, an enzyme known to play a critical role in cellul
52 c2 as a novel mediator of cross-talk between PI-3K and the p21(ras)-ERK pathway which functions to al
53 ced NOi release requires stimulation of both PI-3K/Akt and IP3-dependent Ca2+ signalling.
54 hus, we demonstrated p85alpha-associated but PI-3K-independent cell death in response to UVR and iden
55  Bcl-2 family, an effect that was blocked by PI-3K inhibitors but not by ERK1/2 inhibition.
56 utralization of virus entry and infection by PI-3K and other cellular tyrosine kinase inhibitors sugg
57 of the Bcl-2 family), which was inhibited by PI-3K inhibitors, but not by the p70 S6K inhibitor rapam
58 s phosphorylation appears to be regulated by PI-3K activity.
59 actors FOXO1 or KLF2, which are repressed by PI-3K signaling.
60 ts indicate that Th17 cytokines are tuned by PI-3K signaling in CCR6(+) T(M) cells, which may contrib
61 analysis demonstrates that the Ras-dependent PI-3K pathway is also critical for controlling Myc prote
62                                Two different PI-3K inhibitors, wortmannin and LY294002, showed Akt-in
63 ggest that cytokine receptors lacking direct PI-3K binding sites activate Akt via a Shc/Grb2/Gab2/PI-
64  Id1 expression correlates with dysregulated PI-3K signaling in multiple established GBM cell lines.
65 e beta(2)-AR-stimulated changes in MAPK/ERK, PI-3K, and Akt/protein kinase B.
66                       Therefore, we examined PI-3K-deficient embryos generated by a targeted deletion
67                                     Finally, PI-3K inhibition increases PPM1G activity when assessed
68 ect, suggesting an alternative mechanism for PI-3K-dependent regulation of Id1 translation.
69 hat removal of a minimal domain required for PI-3K signaling abrogated the ability of EPO to override
70 her, these findings suggest a novel role for PI-3K/Akt pathways in the modulation of growth arrest re
71 nding sites activate Akt via a Shc/Grb2/Gab2/PI-3K pathway, thereby regulating cell survival and/or p
72  proteins, we show that Ras and Rac GTPases, PI-3K, and PKC participate in cell migration mediated by
73 ults suggest that activation of Akt1 by HER2/PI-3K plays an important role in conferring a broad-spec
74 , we delineated a pathway that involves HER2/PI-3K/Akt in mediating multidrug resistance in human bre
75            Collectively, these data identify PI-3K as an important regulator of HSC function and pote
76 HSC/P) function, and recent studies identify PI-3K as a therapeutic target in treating different leuk
77 dstone, United Kingdom) was used to identify PI-3K reaction products.
78 evious reports have suggested that increased PI-3K/Akt or decreased PTEN activity may activate the HI
79                    HHV-8 gB Delta TM-induced PI-3K was essential for the induction of RhoA and Cdc42
80 ceptor (IL-6R) signaling (eg, IKK/NF-kappaB, PI-3K/Akt, and Raf/MAPK) and downstream effectors (eg, p
81 d EGF-induced phosphatidylinositol-3 kinase (PI-3K) and Akt activation.
82 ctivating the phosphatidylinositol-3 kinase (PI-3K) and mitogen-associated protein kinase (MAPK) sign
83 inase C (PKC) and phosphoinositide-3 kinase (PI-3K) appeared to be required for SDF-1alpha-mediated p
84 e presence of phosphatidylinositol-3 kinase (PI-3K) inhibitors (wortmannin and LY294002), HGF did not
85    Class I(A) phosphatidylinositol-3 kinase (PI-3K) is a lipid kinase, which is activated in blood ce
86 horylates the phosphatidylinositol-3 kinase (PI-3K) product PI3,4,5P3.
87 how increased phosphatidylinositol-3 kinase (PI-3K) signaling, we sought to determine whether this pa
88 inhibition of phosphotidylinositol-3 kinase (PI-3K) with LY294002 reverted the radioresistant phenoty
89 antibody, or with inhibitors of PI-3 kinase (PI-3K), c-Jun kinase (JNK), or Akt, suppressed retinal A
90 ibitor of the phosphatidylinositol-3 kinase (PI-3K), LY294002.
91        The role of Src kinases, PI-3 kinase (PI-3K), Rac1, and CD47 was determined by incubating cell
92 press HER3 caused a phosphoinoside-3 kinase (PI-3K)-dependent activation of Akt, and was associated w
93  (Erk1/2) and phosphatidylinositol-3 kinase (PI-3K).
94 d activity of phosphatidylinositol-3 kinase (PI-3K).
95 ced activation of phosphoinositide-3 kinase (PI-3K).
96 essed through the phosphoinositide-3 kinase (PI-3K)/Akt and p53 pathways.
97  can activate phosphatidylinositol-3 kinase (PI-3K)/Akt pathways and plays an important role in media
98  including Stat5, phosphoinositide-3 kinase (PI-3K)/Akt, and p42/44 mitogen-activated protein kinase
99 on and of the phosphatidylinositol-3 kinase (PI-3K)/Akt-1 pathway prevented the action of EGF on TGF-
100 activation of phosphatidylinositol-3 kinase (PI-3K)/Akt/mammalian target of rapamycin (mTOR) and glyc
101 activation of phosphatidylinositol 3'kinase (PI-3K) and its subsequent up-regulation of specific NF-k
102 n as well as phosphatidylinositol-3'-kinase (PI-3K) activity and Akt/protein kinase B phosphorylation
103 ists to activate the phosphatidyl 3'-kinase (PI-3K) prosurvival pathway.
104 ctivation of phosphatidylinositol-3'-kinase (PI-3K).
105 e mediated by phosphatidylinositol 3-kinase (PI-3K) activation.
106 ependent upon phosphatidylinositol 3-kinase (PI-3K) activity as evidenced by inhibition of glucose up
107 ade involving phosphatidylinositol 3-kinase (PI-3K) and Akt.
108 ation of both phosphatidylinositol 3-kinase (PI-3K) and NF-kappaB/Rel transcription factors is crucia
109 activation of phosphatidylinositol 3-kinase (PI-3K) and p38 kinases.
110 ross-talk between phosphoinositide 3-kinase (PI-3K) and the classical p21(ras)-Raf-Mek-ERK pathway to
111 nhibition of phosphatidyl-inositol 3-kinase (PI-3K) by LY294002 in alpha(IIb)beta(3)(+) cells induced
112 ry subunit of phosphatidylinositol 3-kinase (PI-3K) exerted a proapoptotic role in response to UVR th
113               Phosphatidylinositol 3-kinase (PI-3K) has been linked to promitogenic responses in sple
114 A or with the phosphatidylinositol 3-kinase (PI-3K) inhibitors wortmannin and LY294002 blocked the ea
115 unit (p85) of the phosphoinositide 3-kinase (PI-3K) is homologous with the Cdc42GAP and contains the
116 inhibition of phosphatidylinositol 3-kinase (PI-3K) or adenovirus expression of PTEN or dominant nega
117     Inhibition of phosphoinositide 3-kinase (PI-3K) or Akt signaling selectively prevents Th17 cytoki
118 eceptors (VEGFRs), phosphoinositol 3-kinase (PI-3K) or Rac1 was measured in CECs cocultured in contac
119 target of the phosphatidylinositol 3-kinase (PI-3K) pathway.
120 embers of the phosphatidylinositol 3-kinase (PI-3K) related kinase (PIKK) family unexpectedly reveale
121 igate whether phosphatidylinositol 3-kinase (PI-3K) signaling is involved in lens epithelial cell pro
122 nt activation of phosphoinositidyl 3-kinase (PI-3K) signaling.
123 y blockade of phosphatidylinositol 3-kinase (PI-3K) with wortmannin and LY 294002.
124 that the specific phosphoinositide 3-kinase (PI-3K), Akt and mammalian target of rapamycin (mTOR) inh
125 activation of phosphotidylinositol 3-kinase (PI-3K), Akt and p70 S6 kinase (p70S6k).
126 activation of phosphatidylinositol 3-kinase (PI-3K), Akt, and p70 S6 kinase (p70(S6k)).
127 FAK), Src, c-Cbl, phosphoinositide 3-kinase (PI-3K), and Rho-GTPases.
128  kinase (MAPK) and phosphoinositol 3-kinase (PI-3K), leading to both proliferative and antiapoptotic
129 y blockade of phosphatidylinositol-3-kinase (PI-3K), mammalian target of rapamycin (mTOR), and p38 MA
130               The phosphoinosotide 3-kinase (PI-3K)-Akt/protein kinase B (PKB) pathway has been shown
131 ctivated in a phosphatidylinositol 3-kinase (PI-3K)-dependent manner.
132 d through the phosphatidylinositol 3-kinase (PI-3K)-dependent pathway because inhibitors of PI-3K as
133 phorylation via a phosphoinositide 3-kinase (PI-3K)-dependent process.
134  inhibitor of phosphatidylinositol 3-kinase (PI-3K)-related PKs, including the catalytic subunit of D
135 activation of phosphatidylinositol 3-kinase (PI-3K).
136 horylation of phosphatidylinositol 3-kinase (PI-3K).
137 gnized by the phosphatidylinositol 3-kinase (PI-3K).
138 dly activated phosphatidylinositol 3-kinase (PI-3K)/Akt and p90(RSK1) to an extent similar to insulin
139           The phosphotidylinositol 3-kinase (PI-3K)/Akt pathway is critical for B(a)PDE-induced AP-1
140           The phosphatidylinositol-3-kinase (PI-3K)/Akt pathway, but not the Ras-mediated mitogen-act
141 F-1 activated the phosphoinositide 3-kinase (PI-3K)/Akt pathway.
142  receptor-coupled phosphoinositide 3-kinase (PI-3K)/Akt pathway.
143 player in the phosphatidylinositol 3-kinase (PI-3K)/Akt signal transduction pathway.
144 regulation of phosphatidylinositol 3-kinase (PI-3K)/Akt signaling pathway, taken together with the ev
145 ependent on a phosphatidylinositol 3-kinase (PI-3K)/Akt/GSKIIIbeta pathway(s) as indicated by the sup
146 inase (MAPK)/ phosphatidylinositol 3-kinase (PI-3K)/protein kinase-B (AKT)1-dependent manner.
147 RK)1/2 and phosphatidylinositol-3-OH kinase (PI-3K) pathways significantly, albeit partially, decreas
148 itors of phosphatidylinositol 3'(OH)-kinase (PI-3K) activity diminished EEA1 recruitment to newly for
149 10 (PTEN; eg, phosphatidylinositol-3-kinase [PI-3K]) have been reported to enhance axon regeneration
150  inhibitor of phosphatidylinositol-3-kinase, PI-3K) partially inhibited, and GF 109203X (GF, a specif
151                  Phosphoinositide 3-kinases (PI-3Ks) are key enzymes for cell development, activation
152 MEK1/2-p42/44ERK and NF-kappaB pathways link PI-3K activity to Ag receptor-mediated cyclin D2 inducti
153 ion of the signaling intermediates that link PI-3K activity to the cell cycle remains incomplete.
154                        In an attempt to link PI-3K/Akt to caspase inhibition, we evaluated the influe
155 ibitors PP2 and EPA (Src kinases), LY294002 (PI-3K), or NSC23766 (Rac1).
156                       Whereas IGF-1-mediated PI-3K/Akt signaling plays a pivotal role in cell surviva
157         Inhibition of growth factor-mediated PI-3K signaling resulted in the downregulation of Cdc42
158 hanced the IGF-1-, but not the PDGF-mediated PI-3K activation, suggesting a possible integration of F
159                 We propose that Akt mediates PI-3K-dependent p47(phox) phosphorylation, which contrib
160                 Activated Rac, but not MEK1, PI-3K, or Akt, rescues biosynthesis of cyclin D1 and pro
161 ator of mammalian target of rapamycin (mTOR) PI-3K.
162  induced by starvation or inhibition of mTOR/PI-3K was not affected by either DRAM1 or p62 downregula
163 sion of Deltap85 (a dominant-negative mutant PI-3K) impaired B[a]PDE- and 5-MCDE-induced VEGF inducti
164 ion, overexpression of the dominant negative PI-3K mutant delta p85 reduced the induction of VEGF by
165                  Moreover, dominant-negative PI-3K blocks IFN-promoted degradation of kappaBox alpha.
166                Ly294002, a dominant-negative PI-3K construct, and kinase-dead Akt block IFN-promoted
167 94002 (a PI-3K inhibitor), dominant-negative PI-3K, and kinase-dead Akt block IFN-dependent NF-kappaB
168 the cytoplasmic tyrosine kinase Src, but not PI-3K.
169 ignaling pathway that involves activation of PI-3K and Akt.
170                            The activation of PI-3K and its association with specific tyrosine-phospho
171 ease in insulin/IGF-1-mediated activation of PI-3K and its downstream target Akt, with progression of
172   Insulin and IGF-1 stimulated activation of PI-3K in proliferating and differentiating cultures.
173 ap85, impaired B[a]PDE-induced activation of PI-3K, Akt and AP-1 transactivation.
174 ME fraction markedly inhibited activation of PI-3K, Akt, and p70 S6 kinase (p70(S6k)).
175  reveal that integrin-mediated activation of PI-3K-Akt is amplified by integrin-stimulated VEGF expre
176 enhanced stability of c-Myb by activation of PI-3K-dependent pathway(s) might contribute to the highe
177                Thus, selective activation of PI-3K/AKT in astrocytes expressing EGFRvIII appears to b
178 otes myeloma cell migration by activation of PI-3K/PKCmicro and PI-3K/RhoA pathways independent of Ak
179 e for CD40-mediated survival, as blocking of PI-3K activity did not lead to apoptosis of anti-CD40-tr
180                  Further characterization of PI-3K-dependent Id1 regulation reveals that chemical or
181 e signals from IGF-1 bifurcate downstream of PI-3K.
182 tudy we examined the downstream effectors of PI-3K/Akt signaling and their role in cell death after o
183 igration by Rac1 activation independently of PI-3K signaling and may have importance in the developme
184                                Inhibition of PI-3K activity by these inhibitors unexpectedly increase
185           Interestingly, while inhibition of PI-3K and AKT lowers 4E-BP1 phosphorylation and expressi
186                       Chemical inhibition of PI-3K and mitogen-activated protein kinase kinase 1 inhi
187                   In contrast, inhibition of PI-3K blocked the phosphorylation of Akt and GSK-3beta (
188                                Inhibition of PI-3K impaired 5-MCDE-induced AP-1 transactivation, sugg
189      Our studies indicate that inhibition of PI-3K leads to apoptosis in primary cortical astrocytes.
190                      Selective inhibition of PI-3K or Akt activity with their respective dominant-neg
191  regulate the MAPK cascade, as inhibition of PI-3K prevented activation of Mek1/2 and other downstrea
192 veals that chemical or genetic inhibition of PI-3K signaling reduces Id1 protein but not mRNA express
193 ted by chemical and biological inhibition of PI-3K suggestive of cross talk between signaling pathway
194                                Inhibition of PI-3K, Akt, and p70(S6k) by overexpression of a dominant
195                                Inhibition of PI-3K, PKCs, or Rho-associated kinase by pharmacologic i
196 ction correlates with that for inhibition of PI-3K-related protein kinase activity in these cells.
197 uced arrest was abolished by an inhibitor of PI-3K (LY294002) or by overexpression of dominant-negati
198 -3K)-dependent pathway because inhibitors of PI-3K as well as a dominant negative mutant of p85 (PI-3
199 EK inhibitor U0126, but not by inhibitors of PI-3K or Src kinases.
200 tro experiments using chemical inhibitors of PI-3K suggest that this kinase is potentially important
201 , we determined the potential involvement of PI-3K and its downstream kinases on the inhibition of AP
202  cells, suggesting a possible involvement of PI-3K in JSRV and ENTV Env-induced cell transformation.
203 significant differences in the modulation of PI-3K signaling by different growth factors during proli
204 rexpression of a dominant-negative mutant of PI-3K (Deltap85) impaired nickel-induced HIF-1 transacti
205 verexpression of dominant-negative mutant of PI-3K, Deltap85, impaired B[a]PDE-induced activation of
206       A balance between the nonactivation of PI-3K and the activation of Erk2 may be necessary during
207                                  Products of PI-3K activate several kinases, including the serine/thr
208  leptin promoter, whereas down-regulation of PI-3K influenced only HIF-1alpha binding.
209   In contrast to the absolute requirement of PI-3K and NF-kappaB/Rel for proliferation, these signali
210                         However, the role of PI-3K in regulating fetal liver or adult hematopoiesis i
211        After stimulation, the p85 subunit of PI-3K was associated with 100- and 180-kDa tyrosine phos
212  direct binding sites for the p85 subunit of PI-3K, others, such as the interleukin-3 (IL-3) receptor
213 odies against p85, the regulatory subunit of PI-3K.
214  p85alpha and p85beta regulatory subunits of PI-3K (p85alpha-/-p85beta+/-).
215  also demonstrated that GSK-3 is a target of PI-3K/Akt-1.
216 -3K inhibitors, which inhibit all classes of PI-3Ks, the p85alpha regulatory subunit is not required
217                   PC3 cells are dependent on PI-3K for survival and undergo caspase-dependent death w
218             FGF-2 showed no direct effect on PI-3K activation.
219 ing in Amo and that restoration of GM-CSF or PI-3K signaling will improve host response to the organi
220 s/mitogen-activated protein kinase (MAPK) or PI-3K.
221 ownstream mediators of Ras signaling (MEK or PI-3K) abrogated endothelial cell migration, invasion, a
222                                     Overall, PI-3K signaling appears to enhance Id1 translation with
223 s well as a dominant negative mutant of p85 (PI-3K subunit) reversed the inhibition, whereas a consti
224 ion, as well as to activate survival-related PI-3K/AKT pathways protecting cells from apoptosis.
225                                The selective PI-3K inhibitor, LY 294002, also blocked beta(2)-AR-medi
226 rylation of c-Met, and its downstream signal PI-3K/Akt, but not ERK1/2 or p70S6K.
227                  The presence of significant PI-3K activity throughout the lens further suggests that
228               Pretreatment with the specific PI-3K inhibitor, wortmannin, attenuated IL-10 mediated n
229 uces integrin-dependent pre-existing FAK-Src-PI-3K-Rho GTPase kinases.
230                            Therefore, STAT3, PI-3K, and Akt are components of an IFN signaling pathwa
231 pression of delta-crystallin, but stimulated PI-3K.
232 se (Rpn) 6 subunit and Rpn12, and suppressed PI-3K activity.
233 gh a different mechanism by mainly targeting PI-3K/Akt signaling pathways.
234                            Pyk2, rather than PI 3K/Akt or Erk, appears to be the key downstream effec
235 thway, taken together with the evidence that PI-3K/Akt plays an important role in the activation of A
236       Considering our previous findings that PI-3K is an upstream mediator for c-Jun/AP-1 activation,
237          Furthermore, our data indicate that PI-3K is indispensable for CD40-mediated NF-kappaB/Rel a
238                    Furthermore, we show that PI-3K activity is necessary for the degradation of cycli
239                          Here we showed that PI-3K class IB and class IA catalytic subunits, p110gamm
240 nduced AP-1 transactivation, suggesting that PI-3K is an upstream kinase involved in AP-1 activation
241                                          The PI-3K inhibitors wortmannin and LY294002 blocked the ins
242                                          The PI-3K pathway was additionally shown to exhibit cross-ta
243                                          The PI-3K/Akt pathway did not affect the HIF-1alpha binding
244 RvIII's differential ability to activate the PI-3K downstream signal may explain why this mutant rece
245 the ability of this integrin to activate the PI-3K-Akt pathway and, consequently, the rapamycin-sensi
246 y mimics the effect of HGF by activating the PI-3K/Akt signal involved in wound healing.
247 F-1 receptor neutralizing antibody aIR3, the PI-3K inhibitor wortmannin, and the heat shock protein-9
248 crophages of antibodies against EEA1 and the PI-3K hVPS34 reduced acquisition of late endocytic marke
249 without the PTP inhibitor bpV(phen), and the PI-3K inhibitors wortmannin and LY294002.
250 he JAK-STAT pathway (unique to TPO), and the PI-3K-AKT axis is differentially involved in TPO- and SD
251 cellular cascade through the ERK 1/2 and the PI-3K/ Akt kinase pathways and that these events could b
252 ctivation of the PI-3K pathways, because the PI-3K inhibitor LY294002 blocks the neuroprotective effe
253 nscription and is partially regulated by the PI-3K and ERK1/2 pathways.
254 w that cyclin D2 induction is blocked by the PI-3K inhibitors wortmannin and LY294002, which coincide
255  morphological changes were inhibited by the PI-3K inhibitors.
256 ses were regulated almost exclusively by the PI-3K pathway, with only minor contributions associated
257 entify a series of downstream targets in the PI-3K pathway, including glycogen synthase kinase-3beta,
258 cose utilization in B cells deficient in the PI-3K regulatory subunit p85alpha.
259 onents by mutant c-Kit, such as those in the PI-3K/Akt pathway, is demonstrated and may also be neede
260 a chronic (2-day) IGF-I exposure induced the PI-3K/Akt pathway only in MCF-7 cells.
261                        Administration of the PI-3K inhibitor LY294002 also reduced JEG-3 proliferatio
262 cells and demonstrate that regulation of the PI-3K pathway plays a key role in these processes.
263   We have therefore examined the role of the PI-3K pathway, and of GSK-3beta, in regulating astrocyte
264 tive effects are linked to activation of the PI-3K pathways, because the PI-3K inhibitor LY294002 blo
265 pid translocation and phosphorylation of the PI-3K substrate Akt and phosphorylation of Akt substrate
266 neurons were linked to the activation of the PI-3K-->pAkt pro-survival pathway and the expression of
267 s important implications for the role of the PI-3K-Akt/PKB-HDM2 pathway in tumor progression and angi
268 ulans, the uvsB gene encodes a member of the PI-3K-related kinase family of proteins.
269 nhibition, we evaluated the influence of the PI-3K/Akt axis on the expression of a member of the inhi
270 8-452) was not affected by inhibition of the PI-3K/Akt pathway and was not enhanced by a proteasome i
271 ith HIF-1 transactivation, inhibition of the PI-3K/Akt pathway by either overexpression of Deltap85 o
272 expression are mediated by inhibition of the PI-3K/Akt pathway.
273 f black raspberries may be inhibition of the PI-3K/Akt/AP-1/VEGF pathway.
274  may be mediated through manipulation of the PI-3K/Akt/mTOR and PI-3K/GSK-3beta/APC pathways.
275 1 mRNA translation through inhibition of the PI-3K/Akt/mTOR/eIF4E-BP signaling pathway and triggering
276 g caspase activation, its stimulation of the PI-3K/p70 S6K cascade promotes proliferation.
277  response to wortmannin, suggesting that the PI-3K-mTOR pathway is required for this induction.
278 findings provide the first evidence that the PI-3K/AKT signaling pathway modulates PPM1G activity res
279  growth factor-I (IGF-I) signals through the PI-3K/Akt survival pathways.
280 he MEK/MAPK inhibitor PD98059 but not to the PI-3K inhibitor LY294002.
281 cial effect of p85alpha was unrelated to the PI-3K-dependent signaling pathway.
282 eptors indicate that Shc also signals to the PI-3K/Akt pathway in response to IL-2.
283 of cytokine stimulation, also signals to the PI-3K/Akt pathway.
284  production possibly by interfering with the PI-3K/Akt/mTOR signaling pathway.
285                                   Within the PI-3K cascade, inhibition of p70S6 kinase led to signifi
286  the activity of the core components of the 'PI-3K/Akt pathway' is modulated by a complex network of
287 F induction by B[a]PDE and 5-MCDE is through PI-3K/AP-1-dependent and HIF-1alpha-independent pathways
288 and this AP-1 induction was specific through PI-3K/Akt/JNKs-dependent and p70S6k-independent pathways
289 ogen synthase kinase 3beta and Foxo1 are two PI-3K-regulated targets that play important roles, but t
290 itaxel resistance in breast cancer cells via PI-3K/Akt/mTOR signaling pathway-dependent upregulation
291 athy by inducing retinal VEGF expression via PI-3K/Akt, HIF-1alpha, NF-kappaB, and secondarily, JNK/A
292            beta1-Mediated CLAN formation was PI-3K dependent, whereas beta3-mediated CLAN formation w
293 val and undergo caspase-dependent death when PI-3K is inhibited.
294                                However, when PI-3K was inhibited with wortmannin or dominant-negative
295 these events comprise the mechanism by which PI-3K controls cell proliferation.
296 t-1 and describe a unique mechanism in which PI-3K acts as a mediator of antiproliferation in primary
297  was inhibited by pretreatment of cells with PI-3K inhibitors, wortmannin or Ly294002.
298                  In contrast to studies with PI-3K inhibitors, which inhibit all classes of PI-3Ks, t
299 red growth in ER-positive cells treated with PI-3K and ERK1/ERK2 inhibitors, whereas it had no protec
300 sion of c-Myb expression upon treatment with PI-3K inhibitors or co-expression with dominant negative

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top